Skip to main content

Advertisement

Table 3 Overall safety profile and drug doses in the clarithromycin group and placebo group

From: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

  Clarithromycin group, No = 27 Placebo group, No = 31
120/180 days follow-up—% 77.8% (63.6%; 95.2%) 90.3% (80.5%; 100%)
Treatment cycles—no. (%)
 1 1 (3.7%) 2 (6.4%)
 2 3 (11.1%) 1 (3.2%)
 3 16 (59.3%) 19 (61.2%)
 4 7 (25.9%) 9 (29.0%)
Any adverse event—no. (%) 26 (96.3%) 28 (90.3%)
Any ≥ 3 adverse event—no. (%) 16 (59.3%) 12 (38.7%)
Any serious adverse event—no. (%) 16 (59.3%) 10 (32.3%)
Adverse event resulting in dose reduction of study drug—no. (%) 9 (33.3%) 3 (9.7%)a
Adverse event resulting in dose reduction of bortezomib—no. (%) 9 (33.3%) 4 (12.9%)b
Adverse event resulting in dose reduction of dexamethasone—no. (%) 9 (33.3%) 3 (9.7%)a
Adverse event resulting in dose reduction of cyclophosphamide—no. (%) 4 (14.8%) 1 (3.2%)b
  1. ap = 0.049 (Fisher’s exact test)
  2. bNot significant (Fisher’s exact test)